Skip to main content

Table 2 SCH prevalence reduction in all arms by KK and CCA (when trace was considered positive [CCA+] or negative [CCA−])

From: Progress in controlling the transmission of schistosome parasites in Southern Ethiopia: the Geshiyaro Project in the Wolaita Zone

Arm

S. mansoni prevalence (% and 95% CI)

S. haematobium prevalence (%)

 

Survey

KK

P-value

POC-CCA+

P-value

POC-CCA−

P-value

Urine filtration

Arm 1 pilot

Baseline

0.4 (0.06,1.4)

0.54

7.1 (5.2, 9.7)

0.09*

2.7 (1.6, 4.6)

0.5

0

FU1

2.7 (1.6, 4.6)

14.8 (12.1, 18.1)

9.1 (7, 11.9)

0

FU2

0.18 (0, 1.2)

14.5 (11.7, 17.8)

6.5 (4.8, 9)

0

FU3

0.17 (0,008, 1.1)

9.9 (7.7, 12.7)

3.4 (2.5, 5.3)

0.3

Arm 1a

Baseline

0.8 (0.4, 1.5)

0.2

23.2 (21, 25.5)

 < 0.0001*

11.2 (9.7, 13.1)

 < 0.0001*

0.1

FU1

0

18.1 (16.3, 20.1)

5.4 (4.4, 6.7)

0

FU2

0.4 (0.2, 0.9)

11.3 (9.8, 13)

7.8 (6.6, 9.3)

0.06

Arm 2b

Baseline

3.6 (2.8, 4.5)

 < 0.0001*

20.2 (18.5, 22)

 < 0.0001*

15.5 (14, 17.1)

 < 0.0001*

0

FU1

1.9 (1.4, 2.6)

12.6 (11.2, 14.1)

6.9 (5.9, 8.1)

0

FU2

0.6 (0.3, 1)

12.5 (11.1, 14)

8.1 (7, 9.3)

0

Arm 3c

Baseline

0.4 (0.17, 0.75)

0.12

31.6 (26.7, 33.6)

 < 0.0001*

17.7 (16.1, 19.4)

0.05

0.09

FU1

0.13 (0.03, 0.4)

20 (18.4, 21.8)

15.5 (14.1, 17.1)

0

  1. *Statistically significant; CI confidence interval; BL baseline; FU follow-up; CCA+ cathodic circulating antigen when trace considered positive; CCA− cathodic circulating antigen when trace considered negative
  2. aIn Arm 1 pilot: FU1 was in 2019, FU2 was in 2020, FU3 was in 2021, and FU4 was in 2022
  3. bIn Arm 1 and Arm 2: FU1 was in 2020, FU2 was in 2021, and FU2 was in 2022
  4. cIn Arm 3: FU1 was in 2021, and FU2 was in 2022
Back to article page

Parasites & Vectors

ISSN: 1756-3305

Contact us